XETRA - Delayed Quote EUR

Biogen Inc. (IDP.DE)

144.80

-0.50

(-0.34%)

At close: January 10 at 5:35:47 PM GMT+1

Biogen proposes to buy remaining stake in Sage in $442 million deal

As per the filing, Biogen has a 10.2% stake in Sage Therapeutics. Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects. Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures.

Reuters 23 hours ago

BIIB

SAGE
Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid Cap […]

Insider Monkey yesterday

BIIB
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

BioPharma Dive yesterday

ABBV

PFE

BIIB
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawAmbitious High-Speed Rail Plans Advance in the Baltic RegionA Blueprint for Better Bike LanesNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCompanies including Biogen Inc. and Eli Lilly & Co. h

Bloomberg yesterday

BIIB

LLY

ROG.SW
Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory?

Eli Lilly stock is trading below its key moving averages, but Zepbound just won a new approval. Is LLY stock now a buy?

Investor's Business Daily 2 days ago

LLY

NVO

BIIB
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently shared his perspective on the stock […]

Insider Monkey 3 days ago

BIIB
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index. In order from steepest decline to narrowest, the five unloved were Intel (NASDAQ: INTC), MongoDB (NASDAQ: MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ: MCHP).

Motley Fool 7 days ago

INTC

DXCM

BIIB
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges

Investing.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, expressing concerns over Biogen's near-term revenue mix and the uphill battle in building its Alzheimer’s disease franchise.

Investing.com 9 days ago

BIIB
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 10 days ago

BIIB
The 5 worst performing stocks on the Nasdaq 100 in 2024

AI was huge in 2024. The underperformers list reflects challenges in the other sectors.

TheStreet 10 days ago

INTC

MCHP

DXCM
Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other cheap healthcare stocks. The Resilience and Challenges of Global Healthcare Spending Investing in healthcare equities is typically seen as protective during […]

Insider Monkey 14 days ago

BIIB
Biogen Faces Multiple Analyst Downgrades in December 2024

Skepticism Grows as Sales Projections and Pipeline Prospects Dim

GuruFocus.com 19 days ago

BIIB
BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.

Investing.com 22 days ago

BIIB

MRK
Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead

Investing.com -- Stifel downgraded Biogen Inc (NASDAQ:BIIB) stock to “hold” from “buy” as it noted the company was grappling with a challenging year due to a slow rollout of its Alzheimer’s drug, lecanemab.

Investing.com 26 days ago

BIIB
Netflix, Ford, Biogen: Trending tickers

Morning Brief anchors Seana Smith and Brad Smith discuss Wall Street's latest stock analyst recommendations. Loop Capital downgraded Netflix (NFLX) stock to Hold from Buy while raising the price target to $950 per share, arguing the stock is approaching fair value. Meanwhile, Oppenheimer analysts raised their price target to $1,065 per share, highlighting the company's expansion into live events. Ford (F) shares declined after Jefferies downgraded the automaker to Underperform from Hold. The firm cited several challenges, including inventory overhang and strategic complexities surrounding its European business operations. Additionally, Stifel analysts reduced Biogen's (BIIB) rating to Hold from Buy, noting an absence of clinical catalysts for the upcoming year. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith

Yahoo Finance Video 26 days ago

NFLX

BIIB

F
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 26 days ago

BIIB
Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 20...

Simply Wall St. 30 days ago

BIIB
Biogen reinstated with a Neutral at BofA

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly because Leqembi for Alzheimer’s has launched “too slowly,” the analyst tells investors. The downside “feels limited,” so it is worth tracking as the Leqembi launch picks up, the analyst added. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on BIIB: VOO ETF Update,

TipRanks last month

BIIB
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

Zacks last month

BIIB
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption. The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could pus

Benzinga last month

BIIB

Performance Overview

Return	IDP.DE	S&P 500
YTD	+0.77%	-1.35%
1-Year	-38.33%	+22.51%
3-Year	-29.62%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biogen Inc. (IDP.DE)

Biogen proposes to buy remaining stake in Sage in $442 million deal

Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory?

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The 5 worst performing stocks on the Nasdaq 100 in 2024

Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

Biogen Faces Multiple Analyst Downgrades in December 2024

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead

Netflix, Ford, Biogen: Trending tickers

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?

Biogen reinstated with a Neutral at BofA

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Performance Overview